News | April 01, 2008

TAXUS Outcomes Similar in Diabetic Patients Compared to Non-Diabetics

April 1, 2008 - Despite the known increased rates of mortality and restenosis for diabetics versus non-diabetics in patients with cardiovascular disease, the TAXUS Stent had comparable levels of late loss and target lesion revascularization (TLR) across these patient populations, according to results from TAXUS IV and TAXUS V randomized clinical trials.

The analysis compared the safety and efficacy of the TAXUS Express Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients.

The study also showed no significant differences in target vessel revascularization (TVR), stent thrombosis or myocardial infarction (MI), after adjustments were made for differences in other baseline characteristics between patients with or without diabetes. Analysis of the data was presented by Gregg W. Stone, M.D., of the Columbia University Medical Center in New York, at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago.

"The TAXUS IV/V diabetic subset data indicated that the TAXUS Stent mitigated the impact of diabetes as a risk factor for restenosis following stenting procedures in the patients studied," said Dr. Stone. "Diabetic patients treated with TAXUS Stents compared to bare-metal stents had significantly improved event-free survival, particularly important in high-risk patients with diabetes."

The pooled analysis included angiographic outcomes at nine months and clinical outcomes at three years among 338 diabetic patients and 901 non-diabetic patients treated with the TAXUS Stent from the TAXUS IV and V clinical trials. Nine-month angiographic outcomes showed equivalent in-segment late loss (0.27mm vs. 0.31mm, p=0.28) and binary restenosis (14.3 percent vs. 15.1 percent, p=0.83) in diabetics and non-diabetics, respectively.

At three years, TLR was similar for diabetic and non-diabetic patients (12.4 percent vs. 10.1 percent, p=0.25), despite significant baseline differences and increased comorbidity risk in diabetic patients. TVR was higher in diabetics (21.4 percent vs. 15.7 percent, p=0.017), due to an increase in remote TVR events (outside the stented segment), which is an indicator of the more aggressive background disease progression in diabetics. Three-year rates of stent thrombosis under Protocol definition (0.9 percent vs. 1.3 percent, p=0.63) and ARC Definite/Probable (1.6 percent vs. 1.9 percent, p=0.73) were similar, even without multivariate adjustment.

The TAXUS IV/V analysis also compared 338 diabetic patients treated with the TAXUS Stent versus 336 diabetic patients treated with bare-metal stents (BMS). Three-year rates of TVR and TLR were reduced by roughly 50 percent in diabetic patients treated with the TAXUS Stent compared to BMS, consistent with results seen in other high-risk patient groups. The TAXUS Stent showed comparable safety to BMS in diabetics, with no significant differences in death (7.3 percent vs. 7.1 percent, p=0.91), cardiac death (4.6 percent vs. 2.7 percent, p=0.23), MI (6.5 percent vs. 6.6 percent, p=0.83) or ARC Definite/Probable stent thrombosis (1.6 percent vs. 1.5 percent, p=1.00) in TAXUS and BMS, respectively.

The safety and effectiveness of the TAXUS Express Stent has not been established in patients with diabetes in the United States.

For more information: www.bostonscientific.com

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init